Evaluation
*
HighAbove AverageAverageBelow AverageLow
Donald Harvey, PharmD, FCCP, BCOP
Sukhmani Padda, MD
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Discuss evidence-based guidelines for the biopsy, histology, and molecular testing for diagnostic/prognostic markers
Describe scientific updates and key practice changes in the management of lung cancer, focusing on targeted including both new and investigational biologic therapies
Identify the common disease symptoms and/or side effects encountered in the management of non=small cell lung cancer and detail the best management strategies utilized by APs in oncology
Describe collaboration between various members of the healthcare team (including but not limited to physician, AP, and pharmacist) in the care of NSCLC
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*